KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Revenue (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Revenue for 16 consecutive years, with $65343.0 as the latest value for Q1 2025.

  • Quarterly Revenue changed N/A to $65343.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $65343.0 through Dec 2025, down 69.99% year-over-year, with the annual reading at $65343.0 for FY2025, 69.99% down from the prior year.
  • Revenue hit $65343.0 in Q1 2025 for Inovio Pharmaceuticals, down from $116994.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.2 million in Q3 2022 to a low of $65343.0 in Q1 2025.
  • Historically, Revenue has averaged $876809.0 across 5 years, with a median of $225971.0 in 2023.
  • Biggest five-year swings in Revenue: soared 3038.22% in 2022 and later tumbled 95.76% in 2023.
  • Year by year, Revenue stood at $839115.0 in 2021, then plummeted by 85.14% to $124666.0 in 2022, then fell by 17.66% to $102651.0 in 2023, then grew by 13.97% to $116994.0 in 2024, then crashed by 44.15% to $65343.0 in 2025.
  • Business Quant data shows Revenue for INO at $65343.0 in Q1 2025, $116994.0 in Q4 2024, and $100762.0 in Q2 2024.